Diabetic Neuropathy Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025

Published on : Apr-2020 | List of Tables : 90 | List of Figures : 67 | No. of Pages : 170 | Report Code : FACT4698MR | Format :

Approval of Novel Drugs to Act as Growth Lever in Diabetic Neuropathy Market, Treatment Modalities to Soar amid COVID-19

As of 2019, nearly 1/10th of the world’s population suffered from diabetes. Consequently, a surge in diabetic treatment has followed, with key pharmaceutical companies investing heavily in developing anti-diabetic formulations.

The approval of novel drugs for the treatment of diabetic neuropathic pain has led to a major uptick in the diabetic drugs market. In 2015, the FDA approved Nucynta ER for the treatment of neuropathic pain caused by diabetes. Another drug, Lyrica, has also been approved for neuropathic pain treatment in 130 countries. On the back of these trends, the global diabetic neuropathy is anticipated to surge at a CAGR of 5.6% during the forecast period (2020-2025).

The recent COVID-19 pandemic is not anticipated to limit production of novel drugs or supplies of insulin to hospitals or pharmacies.However, delays in processing orders may be anticipated.

Peripheral & Proximal Neuropathy to Register Major Usage of Diabetic Neuropathy Formulations

The peripheral neuropathy disorder segment is projected to find increased usage of diabetic neuropathy formulations. The scope for peripheral neuropathy drugs is poised to increase as currently, the treatment for peripheral neuropathy is confined on managing pain rather than regeneration of nerves. Moreover, present underdiagnoses of peripheral neuropathic patients shall broaden prospects for these drugs. Projections indicate a positive CAGR of 5.9%

global diabetic neuropathy market 01

To know more about the diabetic neuropathy market, ask an analyst here

However, proximal neuropathy disorders are anticipated to find substantial applications of neuropathy formulations. Proximal neuropathy is the most common disorder among type 2 diabetics. An increase in the patient pool suffering from proximal neuropathy is thus anticipated to drive the growth of the proximal neuropathy segment, capturing a market share of nearly one-fourth and expanding at a CAGR of 5.6%.

North America to Reign Supreme, Asia-Pacific Shows Lucrative Prospects

North America is anticipated to witness high utilization of diabetic neuropathy drugs during the forecast period. Increasing percentage of patients getting diagnosed and receiving treatment for diabetic neuropathy and research for new drugs and therapies with government support are anticipated to leverage market prospects. This includes clinical studies of genetics and natural history of hereditary neuropathics. The North American region is poised to capture more than two-fifth of the market, expanding 1.4x during the forecast period.

global diabetic neuropathy market 02

For more regional insights on the diabetic neuropathy market, request for a report sample here

Asia-Pacific shows lucrative growth opportunities, expanding 1.5x and capturing over one-fifth of the global diabetic neuropathy market. A large patient pool and supportive government policies are driving the diabetic neuropathy market in Asia-Pacific. Inadequate healthcare infrastructure and poor dietary habits are poised to motivate companies to conduct research and develop new pipeline drugs.

Development of Novel Molecules and Drugs to be Key Growth Stimuli for Market Players

The global diabetic neuropathy market is highly consolidated. The key market players are Arbor Pharmaceuticals, LLC, Pfizer, Inc., Janssen Global Services, LLC, NeuroMatrix, Inc., Depomed, Inc., and Eli Lilly. These companies primarily concentrate on developing new drugs within their pipeline, owing to the burgeoning need for treatment of diabetics.

Janssen Global Services, LLC, the pharmaceutical arm of Johnson & Johnson, manufactures diabetic neuropathy drugs such as NUCYNTA, NUCYNTA ER, Duragesic and INVOKANA. These drugs contain canagliflozin and tapentadol which are important for regulating blood sugar levels. Likewise, Pfizer, Inc., produces Lyrica EH, Celebrex, Lyrica IH and TafamidisMeglumine.

Another prominent market player, Glenmark Pharmaceuticals Ltd., manufactures remoglifozinetabonate, belonging to the gliflozin class to treat type-2 diabetes. Additionally, the company has successfully out-licensed seven novel molecules to leading pharmaceutical giants such as Merck KGaA and remains the only company to execute multiple deals on novel molecules. An example of this is the development of the SGLT2 inhibitor which developed into remoglifozin.

COVID-19 Market Insights

Diabetic patients are indeed extremely vulnerable to serious complications, if infected by the COVID-19 virus. The infection can cause internal swelling and also increase inflammation among diabetic patients. It is, therefore, imperative for hospitals, clinics and surgical centers to ensure that such complications are mitigated by providing advanced medical care. Fortunately, leading manufacturers in the diabetes sector have reported that the COVID-19 is not having an impact on their current manufacturing and distribution capabilities for vital injections such as insulin.

Majority of the players conclude that a shortage of medicines is not anticipated in the forecast period, due to close monitoring of supply chain for potential impacts on sale of medicines. However, delays in processing of orders are projected, attributed to a shift to a remote workforce. Eli Lilly, a diabetic drug manufacturing company, has claimed that its production shall not be hampered as their insulin manufacturing sites across Europe and the United States remain operational amid increased precautions.The company has urged pharmacies receiving insulin supplies from it to place orders directly with the wholesalers in order to avoid a manufacturer backorder. Another player, Mannkind(Afrezza) claims that its U.S. manufacturing plant is fully operational, thus assuring clients that their supplies wouldn’t be impacted. To summarize, the global COVID-19 pandemic is poised to have a negligible restraining impact on the production of diabetic drugs across all regions.

Global Diabetic Neuropathy Market - Scope of the Report

The recent study by Fact.MR on global diabetic neuropathy market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends that arecurrently determining the growth of the global diabetic neuropathy market. This reportexplicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders and emerging players associated with the manufacturing of diabetic neuropathy drugs. The study also provides dynamics that are responsible for influencing the future status of the global diabetic neuropathy market over the forecast period.

A detailed assessment of the global diabetic neuropathy market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the global diabetic neuropathy market along with their product portfolio enhances the reliability of this comprehensive research study.

Global Diabetic Neuropathy Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in global diabetic neuropathy market across the globe.

A comprehensive estimate of the global diabetic neuropathy market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global diabetic neuropathydrugs during the forecast period. Price point comparison by region with global average price is also considered in the study.

Global Diabetic Neuropathy Market Segmentation

Fact.MR has studied the global diabetic neuropathy market with detailed segmentation on the basis of disorder type, treatment type, distribution channel and region.

Disorder Type

Treatment Type

Distribution Channel

Region

 

Peripheral Neuropathy

Drugs:

Analgesic:

Topical:

  • Capsaicin
  • Others

Opioid:

  • Morphine
  • Others

NSAIDs:

  • Ibuprofen
  • Naproxen
  • Others

Antidepressants:

TCAs:

  • Amitriptyline
  • Imipramine
  • Others

SNRIs:

  • Duloxetine
  • Others

SSRIs:

  • Citalopram
  • Paroxetine         
  • Others

Anticonvulsant Drugs:

  • Gabapentin
  • Pregabalin
  • Topiramate
  • Others

Other Drugs

Hospitals

 

North America

Autonomic Neuropathy

Radiotherapy:

  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Others

Clinics

Europe

Proximal Neuropathy

Physiotherapy

Retail Pharmacy

Asia Pacific

Focal Neuropathy

 

Online Pharmacy

Latin America

 

 

 

Middle East & Africa (MEA)

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Global Diabetic Neuropathy Market: Analysis on Market Size Evaluation

The global Diabetic Neuropathy market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regionallevels for Diabetic Neuropathy market is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent diabetic neuropathy market segments, along with market attractiveness evaluation has been incorporated in the report.

Global Diabetic Neuropathy Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global diabetic neuropathy market report, which havehelped deliver projections on regional markets. These chapters include the regional macros (economic and business environment outlook), which are expected to have a momentous influence on the growth of the global diabetic neuropathy market during the forecast period.

Country-specific valuation on demand for diabetic neuropathy has been offered for each regional market, along with the market scope, estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value for emerging countries has also been included in the report.

Global Diabetic Neuropathy Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading manufacturers of global diabetic neuropathy drugs market along with their detailed profiles. Essential and up-to-date data andinformation related to the market performers, who are principally engaged in the production of diabetic neuropathy drugs, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the global diabetic neuropathy market. Prominent manufacturers with established market presence in the global diabetic neuropathy market areJohnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline Plc.,Lupin Limited, Astellas Pharma Inc., Pfizer, Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and Depomed, Inc.

    1. Preface

        1.1. Report Scope and Market Segmentation

        1.2. Research Highlights

    2. Assumptions and Research Methodology

        2.1. Assumptions and Acronyms Used

        2.2. Research Methodology

    3. Executive Summary

        3.1. Global Diabetic Neuropathy Market Size (US$ Mn) and Forecast, by Region, 2020 and 2025

        3.2. Global Diabetic Neuropathy Market: Market Snapshot

    4. Market Overview

        4.1. Global Diabetic Neuropathy Market Overview

        4.2. Global Diabetic Neuropathy Market Key Industry Developments

    5. Market Dynamics

        5.1. Drivers and Restraints Snapshot Analysis

        5.2. Drivers

        5.3. Restraints

        5.4. Opportunities

        5.5. Key Trends

        5.6. Global Diabetic Neuropathy Market: Pipeline Analysis

        5.7. Global Diabetic Neuropathy Market Revenue Projections (US$ Mn), 2020–2025

        5.8. Diabetic Neuropathy Market: Mergers & Acquisitions

        5.9. Regulatory Framework

        5.10. Heat Map Analysis - Company

    6. Global Diabetic Neuropathy Market Analysis, by Disorder Type

        6.1. Introduction

        6.2. Key Insights

        6.3. Global Diabetic Neuropathy Market Size and Forecast, by Disorder Type

            6.3.1. Peripheral Neuropathy

            6.3.2. Autonomic Neuropathy

            6.3.3. Proximal Neuropathy

            6.3.4. Focal Neuropathy

        6.4. Global Diabetic Neuropathy Market Analysis, by Disorder Type

        6.5. Global Diabetic Neuropathy Market Attractiveness Analysis, by Disorder Type

    7. Global Diabetic Neuropathy Market Analysis, by Treatment Type

        7.1. Introduction

        7.2. Key Insights

        7.3. Global Diabetic Neuropathy Market Size and Forecast, by Treatment Type

            7.3.1. Drug

                7.3.1.1. Analgesic

                    7.3.1.1.1. Topical (Capsaicin & Others)

                    7.3.1.1.2. Opioids (Morphine & Others)

                    7.3.1.1.3. NSAIDs (Ibuprofen, Naproxen & Others)

                7.3.1.2. Antidepressant

                    7.3.1.2.1. TCAs (Amitriptyline, Imipramine & Others)

                    7.3.1.2.2. SNRIs (Duloxetine & Others)

                    7.3.1.2.3. SSRIs (Citalopram, Paroxetine & Others)

                7.3.1.3. Anticonvulsants

                    7.3.1.3.1. Gabapentin

                    7.3.1.3.2. Pregabalin

                    7.3.1.3.3. Topiramate

                    7.3.1.3.4. Others

                7.3.1.4. Other Drugs

            7.3.2. Radiotherapy

                7.3.2.1. TENS

                7.3.2.2. Others

            7.3.3. Physiotherapy

        7.4. Global Diabetic Neuropathy Market Analysis, by Treatment Type

        7.5. Global Diabetic Neuropathy Market Attractiveness Analysis, by Treatment Type

    8. Global Diabetic Neuropathy Market Analysis, by Distribution Channel

        8.1. Introduction

        8.2. Key Insights

        8.3. Global Diabetic Neuropathy Market Size and Forecast, by Distribution Channel

            8.3.1. Hospitals

            8.3.2. Clinics

            8.3.3. Retail Pharmacy

            8.3.4. Online Pharmacy

        8.4. Global Diabetic Neuropathy Market Analysis, by Distribution Channel

        8.5. Global Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel

    9. Global Diabetic Neuropathy Market Analysis, by Region

        9.1. Introduction

        9.2. Key Insights

        9.3. Global Diabetic Neuropathy Market Size and Forecast , by Region, 2014–2025

            9.3.1. North America

            9.3.2. Europe

            9.3.3. Asia Pacific

            9.3.4. Latin America

            9.3.5. Middle East & Africa

        9.4. Global Diabetic Neuropathy Market Analysis, by Region

        9.5. Global Diabetic Neuropathy Market Attractiveness Analysis, by Region

    10. North America Diabetic Neuropathy Market Analysis

        10.1. North America Diabetic Neuropathy Market Key Findings

        10.2. North America Diabetic Neuropathy Market Overview

        10.3. North America Diabetic Neuropathy Market Size and Forecast, by Disorder Type

            10.3.1. Peripheral Neuropathy

            10.3.2. Autonomic Neuropathy

            10.3.3. Proximal Neuropathy

            10.3.4. Focal Neuropathy

        10.4. North America Diabetic Neuropathy Market Analysis, by Disorder Type

        10.5. North America Diabetic Neuropathy Market Size and Forecast, by Treatment Type

            10.5.1. Drug

                10.5.1.1. Analgesic

                    10.5.1.1.1. Topical (Capsaicin & Others)

                    10.5.1.1.2. Opioids (Morphine & Others)

                    10.5.1.1.3. NSAIDs (Ibuprofen, Naproxen & Others)

                10.5.1.2. Antidepressant

                    10.5.1.2.1. TCAs (Amitriptyline, Imipramine & Others)

                    10.5.1.2.2. SNRIs (Duloxetine & Others)

                    10.5.1.2.3. SSRIs (Citalopram, Paroxetine & Others)

                10.5.1.3. Anticonvulsants

                    10.5.1.3.1. Gabapentin

                    10.5.1.3.2. Pregabalin

                    10.5.1.3.3. Topiramate

                    10.5.1.3.4. Others

                10.5.1.4. Other Drugs

            10.5.2. Radiotherapy

                10.5.2.1. TENS

                10.5.2.2. Others

            10.5.3. Physiotherapy

        10.6. North America Diabetic Neuropathy Market Analysis, by Treatment Type

        10.7. North America Diabetic Neuropathy Market Size and Forecast, by Distribution Channel

            10.7.1. Hospitals

            10.7.2. Clinics

            10.7.3. Retail Pharmacy

            10.7.4. Online Pharmacy

        10.8. North America Diabetic Neuropathy Market Analysis, by Distribution Channel

        10.9. North America Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel

        10.10. North America Diabetic Neuropathy Market Forecast, by Country

            10.10.1. U.S.

            10.10.2. Canada

        10.11. North America Diabetic Neuropathy Market Attractiveness Analysis 

            10.11.1. By Disorder Type

            10.11.2. By Treatment Type

            10.11.3. By Distribution Channel

            10.11.4. By Country

    11. Europe Diabetic Neuropathy Market Analysis

        11.1. Europe Diabetic Neuropathy Market Key Findings

        11.2. Europe Diabetic Neuropathy Market Overview

        11.3. Europe Diabetic Neuropathy Market Size and Forecast, by Disorder Type

            11.3.1. Peripheral Neuropathy

            11.3.2. Autonomic Neuropathy

            11.3.3. Proximal Neuropathy

            11.3.4. Focal Neuropathy

        11.4. Europe Diabetic Neuropathy Market Size and Forecast, by Treatment Type

            11.4.1. Drug

                11.4.1.1. Analgesic

                    11.4.1.1.1. Topical (Capsaicin & Others)

                    11.4.1.1.2. Opioids (Morphine & Others)

                    11.4.1.1.3. NSAIDs (Ibuprofen, Naproxen & Others)

                11.4.1.2. Antidepressant

                    11.4.1.2.1. TCAs (Amitriptyline, Imipramine & Others)

                    11.4.1.2.2. SNRIs (Duloxetine & Others)

                    11.4.1.2.3. SSRIs (Citalopram, Paroxetine & Others)

                11.4.1.3. Anticonvulsants

                    11.4.1.3.1. Gabapentin

                    11.4.1.3.2. Pregabalin

                    11.4.1.3.3. Topiramate

                    11.4.1.3.4. Others

                11.4.1.4. Other Drugs

            11.4.2. Radiotherapy

                11.4.2.1. TENS

                11.4.2.2. Others

            11.4.3. Physiotherapy

        11.5. Europe Diabetic Neuropathy Market Size and Forecast, by Distribution Channel

            11.5.1. Hospitals

            11.5.2. Clinics

            11.5.3. Retail Pharmacy

            11.5.4. Online Pharmacy

        11.6. Europe Diabetic Neuropathy Market Analysis, by Distribution Channel

        11.7. Europe Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel

        11.8. Europe Diabetic Neuropathy Market Forecast, by Country

            11.8.1. Germany

            11.8.2. U.K.

            11.8.3. France

            11.8.4. Spain

            11.8.5. Italy

            11.8.6. Rest of Europe

        11.9. Europe Diabetic Neuropathy Market Attractiveness Analysis

            11.9.1. By Disorder Type

            11.9.2. By Treatment Type

            11.9.3. By Distribution Channel

            11.9.4. By Country

    12. Asia Pacific Diabetic Neuropathy Market Analysis

        12.1. Asia Pacific Diabetic Neuropathy Market Key Findings

        12.2. Asia Pacific Diabetic Neuropathy Market Overview

        12.3. Asia Pacific Cytometry Market Size and Forecast, by Disorder Type

            12.3.1. Peripheral Neuropathy

            12.3.2. Autonomic Neuropathy

            12.3.3. Proximal Neuropathy

            12.3.4. Focal Neuropathy

        12.4. Asia Pacific Diabetic Neuropathy Market Size and Forecast, by Treatment Type

            12.4.1. Drug

                12.4.1.1. Analgesic

                    12.4.1.1.1. Topical (Capsaicin & Others)

                    12.4.1.1.2. Opioids (Morphine & Others)

                    12.4.1.1.3. NSAIDs (Ibuprofen, Naproxen & Others)

                12.4.1.2. Antidepressant

                    12.4.1.2.1. TCAs (Amitriptyline, Imipramine & Others)

                    12.4.1.2.2. SNRIs (Duloxetine & Others)

                    12.4.1.2.3. SSRIs (Citalopram, Paroxetine & Others)

                12.4.1.3. Anticonvulsants

                    12.4.1.3.1. Gabapentin

                    12.4.1.3.2. Pregabalin

                    12.4.1.3.3. Topiramate

                    12.4.1.3.4. Others

                12.4.1.4. Other Drugs

            12.4.2. Radiotherapy

                12.4.2.1. TENS

                12.4.2.2. Others

            12.4.3. Physiotherapy

        12.5. Asia Pacific Diabetic Neuropathy Market Size and Forecast, by Distribution Channel

            12.5.1. Hospitals

            12.5.2. Clinics

            12.5.3. Retail Pharmacy

            12.5.4. Online Pharmacy

        12.6. Asia Pacific Diabetic Neuropathy Market Analysis, by Distribution Channel

        12.7. Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis, by Distribution Channel

        12.8. Asia Pacific Diabetic Neuropathy Market Forecast, by Country

            12.8.1. China

            12.8.2. India

            12.8.3. Japan

            12.8.4. Australia & New Zealand

            12.8.5. Rest of Asia Pacific

        12.9. Asia Pacific Diabetic Neuropathy Market Attractiveness Analysis 

            12.9.1. By Disorder Type

            12.9.2. By Treatment Type

            12.9.3. By Distribution Channel

            12.9.4. By Country

    13. Latin America Diabetic Neuropathy Market Analysis

        13.1. Latin America Diabetic Neuropathy Market Key Findings

        13.2. Latin America Diabetic Neuropathy Market Overview

        13.3. Latin America Cytometry Market Size and Forecast, by Disorder Type

            13.3.1. Peripheral Neuropathy

            13.3.2. Autonomic Neuropathy

            13.3.3. Proximal Neuropathy

            13.3.4. Focal Neuropathy

        13.4. Latin America Diabetic Neuropathy Market Size and Forecast, by Treatment Type

            13.4.1. Drug

                13.4.1.1. Analgesic

                    13.4.1.1.1. Topical (Capsaicin & Others)

                    13.4.1.1.2. Opioids (Morphine & Others)

                    13.4.1.1.3. NSAIDs (Ibuprofen, Naproxen & Others)

                13.4.1.2. Antidepressant

                    13.4.1.2.1. TCAs (Amitriptyline, Imipramine & Others)

                    13.4.1.2.2. SNRIs (Duloxetine & Others)

                    13.4.1.2.3. SSRIs (Citalopram, Paroxetine & Others)

                13.4.1.3. Anticonvulsants

                    13.4.1.3.1. Gabapentin

                    13.4.1.3.2. Pregabalin

                    13.4.1.3.3. Topiramate

                    13.4.1.3.4. Others

                13.4.1.4. Other Drugs

            13.4.2. Radiotherapy

                13.4.2.1. TENS

                13.4.2.2. Others

            13.4.3. Physiotherapy

        13.5. Latin America Diabetic Neuropathy Market Size and Forecast, by Distribution Channel

            13.5.1. Hospitals

            13.5.2. Clinics

            13.5.3. Retail Pharmacy

            13.5.4. Online Pharmacy

        13.6. Latin America Diabetic Neuropathy Market Analysis, by Distribution Channel

        13.7. Latin America Diabetic Neuropathy Market Forecast, by Country

            13.7.1. Brazil

            13.7.2. Mexico

            13.7.3. Rest of Latin America

        13.8. Latin America Diabetic Neuropathy Market Attractiveness Analysis

            13.8.1. By Disorder Type

            13.8.2. By Treatment Type

            13.8.3. By Distribution Channel

            13.8.4. By Country

    14. Middle East & Africa Diabetic Neuropathy Market Analysis

        14.1. Middle East & Africa Diabetic Neuropathy Market Key Findings

        14.2. Middle East & Africa Diabetic Neuropathy Market Overview

        14.3. Middle East & Africa Cytometry Market Size and Forecast, by Disorder Type

            14.3.1. Peripheral Neuropathy

            14.3.2. Autonomic Neuropathy

            14.3.3. Proximal Neuropathy

            14.3.4. Focal Neuropathy

        14.4. Middle East & Africa Diabetic Neuropathy Market Size and Forecast, by Treatment Type

            14.4.1. Drug

                14.4.1.1. Analgesic

                    14.4.1.1.1. Topical (Capsaicin & Others)

                    14.4.1.1.2. Opioids (Morphine & Others)

                    14.4.1.1.3. NSAIDs (Ibuprofen, Naproxen & Others)

                14.4.1.2. Antidepressant

                    14.4.1.2.1. TCAs (Amitriptyline, Imipramine & Others)

                    14.4.1.2.2. SNRIs (Duloxetine & Others)

                    14.4.1.2.3. SSRIs (Citalopram, Paroxetine & Others)

                14.4.1.3. Anticonvulsants

                    14.4.1.3.1. Gabapentin

                    14.4.1.3.2. Pregabalin

                    14.4.1.3.3. Topiramate

                    14.4.1.3.4. Others

                14.4.1.4. Other Drugs

            14.4.2. Radiotherapy

                14.4.2.1. TENS

                14.4.2.2. Others

            14.4.3. Physiotherapy

        14.5. Middle East & Africa Diabetic Neuropathy Market Size and Forecast, by Distribution Channel

            14.5.1. Hospitals

            14.5.2. Clinics

            14.5.3. Retail Pharmacy

            14.5.4. Online Pharmacy

        14.6. Middle East & Africa Diabetic Neuropathy Market Analysis, by Distribution Channel

        14.7. Middle East & Africa Diabetic Neuropathy Market Size and Forecast, by Country

            14.7.1. GCC Countries

            14.7.2. Israel

            14.7.3. South Africa

            14.7.4. Rest of Middle East & Africa

        14.8. Middle East Diabetic Neuropathy Market Attractiveness Analysis

            14.8.1. By Disorder Type

            14.8.2. By Treatment Type

            14.8.3. By Distribution Channel 

            14.8.4. By Country

    15. Competition Landscape

        15.1. Global Diabetic Neuropathy Market Share Analysis, by Company (2018)

        15.2. Company Profiles

            15.2.1. Johnson & Johnson (Janssen Global Services, LLC)

                15.2.1.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.1.2. Financials

                15.2.1.3. Recent Developments

                15.2.1.4. Strategy

            15.2.2. Boehringer Ingelheim GmbH

                15.2.2.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.2.2. Financials

                15.2.2.3. Recent Developments

                15.2.2.4. Strategy

            15.2.3. NeuroMetrix, Inc.

                15.2.3.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.3.2. Financials

                15.2.3.3. Recent Developments

                15.2.3.4. Strategy

            15.2.4. Eli Lilly and Company

                15.2.4.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.4.2. Financials

                15.2.4.3. Recent Developments

                15.2.4.4. Strategy

            15.2.5. Lupin Limited

                15.2.5.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.5.2. Financials

                15.2.5.3. Recent Developments

                15.2.5.4. Strategy

            15.2.6. GlaxoSmithKline plc

                15.2.6.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.6.2. Financials

                15.2.6.3. Recent Developments

                15.2.6.4. Strategy

            15.2.7. Astellas Pharma Inc.

                15.2.7.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.7.2. Financials

                15.2.7.3. Recent Developments

                15.2.7.4. Strategy

            15.2.8. Glenmark Pharmaceuticals Ltd 

                15.2.8.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.8.2. Financials

                15.2.8.3. Recent Developments

                15.2.8.4. Strategy

            15.2.9. Pfizer, Inc.

                15.2.9.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.9.2. Financials

                15.2.9.3. Recent Developments

                15.2.9.4. Strategy

            15.2.10. Arbor Pharmaceuticals, LLC

                15.2.10.1. Overview (HQ, Employee Strength, Business Segments)

                15.2.10.2. Financials

                15.2.10.3. Recent Developments

                15.2.10.4. Strategy

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Diabetic Neuropathy Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025